The epidemiology of PSP

  • L. I. Golbe
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 42)


The age-adjusted prevalence of PSP as measured in central New Jersey is 1.5 cases per million population, about 1% of that of Parkinson’s disease. Its incidence is 3–4 new cases per million population per year, similar to that of such better-known illnesses as myasthenia gravis, the hereditary ataxias as a group and Tourette syndrome. Median actuarially adjusted survival after symptom onset is 5.9–6.9 years. PSP appears to favor no geographical, racial, ethnic or occupational group, though there is anecdotal evidence for hydrocarbon exposure as a candidate etiologic factor. No familial cases of typical PSP have been proven. The one formal case-control study failed to implicate any particular causal agent and the rural predilection of PD appears to be absent in PSP. Better diagnostic methods, more multi-center organization, additional case-control studies and new etiologic hypotheses are needed in the epidemiological investigation of PSP.


Tourette Syndrome Progressive Supranuclear Palsy Hereditary Ataxia Olivopontocerebellar Atrophy Pseudobulbar Palsy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. David NJ, Mackey EA, Smith JL (1968) Further observations in progressive supranuclear palsy. Neurology 18: 349–356.PubMedCrossRefGoogle Scholar
  2. Davis PH, Golbe LI, Duvoisin RC, Schoenberg BS (1988) Risk factors for progressive supranuclear palsy. Neurology 38: 1546–1552.PubMedCrossRefGoogle Scholar
  3. Golbe LI, Davis PH, Schoenberg BS, Duvoisin RC (1988) Prevalence and natural history of progressive supranuclear palsy. Neurology 38: 1031–1034.PubMedCrossRefGoogle Scholar
  4. Golbe LI (1991) Young-onset Parkinson’s disease: a clinical review. Neurology 41: 168–173.PubMedCrossRefGoogle Scholar
  5. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427–442.PubMedCrossRefGoogle Scholar
  6. Hynd GW, Pirozzolo FJ, Maletta GJ (1982) Progressive supranuclear palsy. Int J Neurosci 16: 87–98.PubMedCrossRefGoogle Scholar
  7. Jackson JA, Jankovic J, Ford J (1983) Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol 13: 273–278.PubMedCrossRefGoogle Scholar
  8. Kessler II (1972) Epidemiologic study of Parkinson’s disease. Am J Epidemiol 96: 242–254.PubMedGoogle Scholar
  9. Maher ER, Lees AJ (1986) The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 36: 1005–1008.PubMedCrossRefGoogle Scholar
  10. Mastaglia FL, Grainger K, Kee F, Sadka M, Lefroy R (1973) Progressive supranuclear palsy (the Steele-Richardson-Olszewski syndrome): clinical and electrophysiological observations in eleven cases. Proc Aust Assoc Neurol 10: 35–44.PubMedGoogle Scholar
  11. Mata M, Dorovini-Zis K, Wilson M, Young AB (1983) New form of familial Parkinson-dementia syndrome: clinical and pathologic findings. Neurology 33: 1439–1443.PubMedCrossRefGoogle Scholar
  12. McCrank E, Rabheru K (1989) Four cases of progressive supranuclear palsy in patients exposed to organic solvents. Can J Psychiatry 34: 934–935.PubMedGoogle Scholar
  13. McCrank E (1990) PSP risk factors. Neurology 40: 1637.PubMedCrossRefGoogle Scholar
  14. Mutch WJ, Dingwall-Fordyce I, Downie AW, Paterson JG, Roy SK (1986) Parkinson’s disease in a Scottish city. Br Med J 292: 534–536.CrossRefGoogle Scholar
  15. Ohara S, Kondo K, Morita H, Maruyama K, Ikeda S, Yanagisawa N (1992) Progressive supranuclear palsy-like syndrome in two siblings of a consanguineous marriage. Neurology 42: 1009–1014.PubMedCrossRefGoogle Scholar
  16. Pezzoli G, Ricciardi S, Masotta C, Mariani CB, Carenzi A (1990) n-Hexane induces parkinsonism in rodents. Brain Res 531: 355–357.PubMedCrossRefGoogle Scholar
  17. Rajput AH, Offord KP, Beard CM, Kurland LT (1984) Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 16: 278–282.PubMedCrossRefGoogle Scholar
  18. Steele JC, Richardson JC, Olszewski J (1964) Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum, with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 10: 333–359.PubMedCrossRefGoogle Scholar
  19. Steele JC (1972) Progressive supranuclear palsy. Brain 95: 693–704.PubMedGoogle Scholar
  20. Tanner CM, Langston JW (1990) Do environmental toxins cause Parkinson’s disease? A critical review. Neurology 40[Suppl] 3: 17–30.Google Scholar
  21. Tetrud JW, Langston JW, Irwin I, Snow B (1990) Acute and persistent parkinsonism associated with ingestion of petroleum product mixture. Ann Neurol 28: 296.Google Scholar
  22. Vieregge P, Glaese A, Ulm G, Kompf D (1992) Familial Parkinson’s disease. Mov Disord 7[Suppl] 1: 23.Google Scholar

Copyright information

© Springer-Verlag Wien 1994

Authors and Affiliations

  • L. I. Golbe
    • 1
    • 2
  1. 1.Department of NeurologyUniversity of Medicine and Dentistry of New Jersey — Robert Wood Johnson Medical SchoolNew BrunswickUSA
  2. 2.Department of NeurologyUMDNJ-Robert Wood Johnson Medical SchoolNew BrunswickUSA

Personalised recommendations